Hematologic neoplasms represent 6.5% of all cancers worldwide. They are characterized by
the uncontrolled growth of hematopoietic and lymphoid cells and a decreased immune …

Multiple Myeloma (MM) remains an incurable plasma cell neoplasm. Although little is known
about the etiology of MM, several metabolic risk factors such as obesity, diabetes mellitus …

Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …

The gut microbiome has been found to play a crucial role in the treatment of multiple
myeloma (MM), which is still considered incurable due to drug resistance. In previous …

Background Gut microbiome alterations are closely related to human health and linked to a
variety of diseases. Although great efforts have been made to understand the risk factors for …

We previously described clinically relevant reductions in fecal microbiota diversity in patients
undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Recipients of high …

Hematological malignancies, including multiple myeloma, lymphoma, and leukemia, are a
heterogeneous group of neoplasms that affect the blood, bone marrow, and lymph nodes …

Purpose: The gut microbiota plays important roles in health and disease. We questioned
whether the gut microbiota and related metabolites are altered in monoclonal …

The role of infection and chronic inflammation in plasma cell disorders (PCD) has been well-
described. Despite not being a diagnostic criterion, infection is a common complication of …

Purpose: Sustained minimal residual disease (MRD) negativity is associated with long-term
survival in multiple myeloma. The gut microbiome is affected by diet, and in turn can …